Skip to content

Cagrilintide: Benefits & Research

Part of the Cagrilintide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Weight Loss

Cagrilintide monotherapy (4.5 mg) produced approximately 10.8% body weight loss over 26 weeks in Phase 2 trials. The CagriSema combination (cagrilintide + semaglutide) demonstrated up to 22.7% weight loss — exceeding either agent alone and representing one of the largest pharmaceutical weight loss results achieved.

Satiety & Appetite Control

Cagrilintide promotes satiety through amylin receptor activation in the area postrema and nucleus tractus solitarius — brain regions that regulate fullness and food intake. This mechanism is distinct from and complementary to GLP-1 signaling, explaining the additive effect in CagriSema.

Metabolic Improvements

Clinical trials show cagrilintide improves glucose homeostasis, reduces HbA1c, and improves insulin sensitivity. The amylin pathway also slows gastric emptying and suppresses inappropriate postprandial glucagon release.

Frequently Asked Questions

References

  1. Lau DCW, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet, 2021.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.